Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518871 | 0.93 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL3517423 | 0.93 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL13434462 | 0.87 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL13903539 | 0.87 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL4403626 | 0.86 | SMN1; SMN2 (0.61) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL4266594 | 0.84 | HSD17B2 (0.54) | NPC1RAB9ASMN1; SMN2SMPD1HDAC6 | |
| SCHEMBL4279981 | 0.84 | HSD17B10 (0.61) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL3517594 | 0.83 | PPIA (0.43) | SMN1; SMN2MEN1KMT2APPIAHSD17B10 | |
| SCHEMBL340393 | 0.83 | SMN1; SMN2 (0.72) | NPC1RAB9ASMN1; SMN2HPGDSMPD1 | |
| SCHEMBL3515803 | 0.80 | CTSV (0.43) | SMN1; SMN2MEN1KMT2AMAPTPPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194787-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009036055-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076044-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076044-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | KDR, HDAC1, FLT4 | NPC1 3312/4885RAB9A 3196/4885SMN1; SMN2 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.